StockNews.com Upgrades MediWound (NASDAQ:MDWD) to “Sell”

MediWound (NASDAQ:MDWD) was upgraded by research analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Friday.

Several other research analysts have also commented on the company. Craig Hallum began coverage on MediWound in a research report on Friday, February 28th. They issued a “buy” rating and a $39.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of MediWound in a report on Thursday.

MediWound Stock Performance

NASDAQ MDWD opened at $16.27 on Friday. The stock has a 50 day moving average price of $18.17 and a 200-day moving average price of $17.59. MediWound has a one year low of $12.78 and a one year high of $24.00. The company has a market capitalization of $175.60 million, a P/E ratio of -5.61 and a beta of 0.82.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.23. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. The company had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.79 million. During the same quarter in the prior year, the firm earned ($0.19) earnings per share. As a group, equities analysts predict that MediWound will post -2.66 EPS for the current fiscal year.

Hedge Funds Weigh In On MediWound

Several hedge funds have recently added to or reduced their stakes in the company. Investor AB purchased a new position in shares of MediWound during the third quarter valued at approximately $15,750,000. Yelin Lapidot Holdings Management Ltd. lifted its stake in shares of MediWound by 13.4% during the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company’s stock worth $15,154,000 after acquiring an additional 100,618 shares during the last quarter. Northern Trust Corp boosted its holdings in MediWound by 94.6% during the 4th quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company’s stock valued at $2,577,000 after acquiring an additional 70,367 shares during the period. State Street Corp grew its position in MediWound by 219.6% in the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock valued at $1,197,000 after acquiring an additional 45,529 shares during the last quarter. Finally, Essex Investment Management Co. LLC increased its stake in MediWound by 30.7% in the fourth quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company’s stock worth $2,651,000 after purchasing an additional 35,012 shares during the period. 46.83% of the stock is currently owned by institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.